Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS: Patient management considerations

BACKGROUND: Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with relapsing-remitting multiple sclerosis (MS), is a disease-modifying therapy with potential immunomodulatory and neuroprotective effects. In clinical trials, DMF was associated with reduced white blood c...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neurol Clin Pract
Hoofdauteurs: Fox, Robert J., Chan, Andrew, Gold, Ralf, Phillips, J. Theodore, Selmaj, Krzysztof, Chang, Ih, Novas, Mark, Rana, Jitesh, Marantz, Jing L.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Lippincott Williams & Wilkins 2016
Onderwerpen:
Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4909524/
https://ncbi.nlm.nih.gov/pubmed/27347439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0000000000000238
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items